Pharmaceutical Technology, Jun 2, 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Jun 2, 2014
Cover Story
Advances in Controlled-Release Drug Delivery
By Adeline Siew, PhD
Industry experts share their perspectives on key advances in controlled-release drug delivery and future innovations in this arena.
Peer-Reviewed
Selecting a Specimen Holder for X-ray Powder Diffraction
By Joseph H. Reibenspies, PhD , Nattamai Bhuvanesh
Specimen mounting in x-ray powder diffraction affects peak positions and intensities.
Featured Content
The Role of Powder Characterization in Continuous Manufacturing
By Jamie Clayton , John Yin
Experimental work on wet granulation demonstrates the use of dynamic powder characterization to support continuous processing for tablet manufacturing.
API Synthesis & Manufacturing
Seeking Alternative Catalyst Solutions
By Cynthia Challener, PhD
Transition metal-containing catalysts are widely used in organic synthesis, but many are based on expensive, rare metals. Researchers are seeking more sustainable alternatives.
Troubleshooting
Gowning Practices Provide Clues to cGMP Compliance
By Eric Bohn
In legacy facilities and as buildings age, ensuring cGMP compliance can become complex. A review of a facility's gowning operations can bring insight into the current state of cGMP compliance. The author presents characteristics to look for and questions to ask.
Regulatory Watch
Global Expansion Shapes Drug Oversight
By Jill Wechsler
Regulators and industry organizations explain policies and standards to manufacturers and authorities in all regions.
Regulating the Environmental Impact of Pharmaceuticals
By Sean Milmo
Concern by environmentalists, regulators and manufacturers rises over the environmental impact of pharmaceuticals.
Packaging Forum
Packaging Innovations Abound
By Hallie Forcinio
New packaging concepts and equipment, including systems for vial handling, printing and labeling, and parenteral packaging, were revealed at INTERPHEX 2014.
Statistical Solutions
Is a Sample Size of n=6 a Magic Number?
By Chris Burgess
Statistical analysis shows how much testing is needed to deliver a reliable estimate result.
Outsourcing Outlook
Outsourcing No Longer Just for Cost-Cutting
By Eric Langer
With budgets growing, clients see CMOs' costs as less crucial.
Inside EDQM
Finished Product Monographs in the European Pharmacopoeia
By Susanne Keitel
The European Pharmacopoeia Commission re-evaluates its policy on the development of monographs for finished drug products.
Global Feature
Brunei's Potential Pharmaceutical Market Growth
By Jane Wan
Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.
Industry Leaders: Q&A
Q&A with Paul Nelles, Vetter Development Service
By Melanie Sena
Paul Nelles of Vetter Development Service discusses prefilled syringes.
Guest Editorial
Bureaucratic Roadblocks Threaten Biopharma Growth
By Jim Greenwood
Protecting intellectual property rights is vital to biopharmaceutical innovation.
Product Spotlight
Bioreactor for Mammalian Cell Culture
By Melanie Sena
Bioreactor for Mammalian Cell Culture
Hybrid Purifer Enhances Efficiency
By Melanie Sena
Hybrid Purifer Enhances Efficiency
Centrifuges Increase Capacity and Flexibility
By Melanie Sena
Centrifuges Increase Capacity and Flexibility
Single-Use Mixing System Improves Performance
By Melanie Sena
Single-Use Mixing System Improves Performance

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here